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Concomitant Bilastine and Montelukast as Additive Therapy for Seasonal Allergic 
Rhinoconjunctivits and Mild-to-Moderate Asthma. The SKY Study 
 
To the Editor  
Histamine and cysteinyl leukotrienes (CysLTs) are potent inflammatory mediators 
involved in both seasonal allergic rhino-conjunctivitis (SARC) and asthma [1,2]. A 
combination therapy against both these agents may provide additive benefit, as demonstrated 
both in vitro [3] and in vivo [4-6].  
 
We compared the efficacy and safety of concomitant therapy with bilastine, a second 
generation H1 anti-histamine [7], and montelukast versus each agent alone in patient with 
SARC and asthma. We hypothesised that bilastine plus montelukast is superior to bilastine 
monotherapy in reducing SARC symptoms after 4 weeks and in improving asthma quality of 
life over a longer time period. 
 
Adult patients with SARC and mild-to-moderate asthma partially controlled [8] by 
beclomethasone dipropionate or equivalent ≤500 μg/d (alone or in combination with long-
term β2-adrenergic bronchodilators) were enrolled. Patients had a post-bronchodilator FEV1 
>70% of the predicted, a skin prick test positive to at least one seasonal allergen tested at 
enrolment or previously reported, and a nasal/ocular Total Symptom Score (TSS) ≥3 [9]. 
Exclusion criteria are reported in the online supplementary. The study (EUDRA-CT 
number:2015-004806-40) was conducted in 50 centres across 6 European countries during 
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the relevant regional pollen season for grasses, trees and weeds, with a double-blind, double-
dummy, randomised, active-controlled, parallel group design (Figure 1). It consisted in a 1-
week screening period followed by 12 weeks of treatment. During the study, patients 
quantified SARC symptoms by TSS, Daytime Nasal Symptom Score (DNSS), and Daytime 
non-Nasal Symptom Score (DNNS); use of rescue medications and occurrence of adverse 
events were noted. During screening, patients’ medical history, vital signs, spirometry results 
and asthma quality of life questionnaire (AQLQ) scores were obtained. AQLQ was re-
assessed after 4 and 12 weeks of treatment; ECG variables, blood and urine samples were re-
obtained at the end of treatments for safety purposes. Enrolled patients were randomly treated 
once daily with bilastine 20 mg plus montelukast 10 mg, or bilastine 20 mg plus placebo or 
montelukast 10 mg plus placebo (Figure 1). Naphazoline nasal spray eye drops, and 
salbutamol inhaler were rescue medications for SARC and acute asthma symptoms. Patients’ 
compliance with treatments was calculated. The primary endpoint was changes in baseline 
TSS values following 4 weeks of treatment [10]. Secondary endpoints were changes in 
baseline TSS values obtained after 1, 2 and 3 weeks of treatment; changes in baseline DNSS 
and DNNSS values obtained after 1, 2, 3 and 4 weeks of treatments; changes in baseline 
AQLQ score after 4 and 12 weeks of treatment. Analyses were performed on the Intention-
To-Treat (ITT) population, i.e. randomised patients who had received at least one treatment 
tablet, had a baseline assessment and at least one assessment of primary efficacy variable 
after the baseline visit. A sensitivity analysis was also performed on the Per-Protocol (PP) 
population, i.e. patients in the ITT population having completed the study without any major 
protocol violation. The effect of each treatment on primary and secondary endpoints, as well 
as on use of rescue medications for SARC and asthma was compared by analysis of 
covariance. A P value <0.05 was considered as significant. Additional details on the methods 
are in the online supplementary.  
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From April to October 2016, we enrolled 454 patients, 419 of whom (299 females, mean 
age 35.2±0.2) were randomised to treatment (ITT population). Of these 419 patients, 387 
completed the study without protocol violations (PP population, Figure E1). Reasons of 
patients exclusion are reported in the Figure E1 (data supplement). Most patients had 
polisensitization to pollens of grasses, trees and weeds. At inclusion, patients’ demographics, 
FEV1, TSS, AQLQ, DNSS and DNNSS were similar in each treatment arm (table E1). All 
treatments significantly (P<0.001) reduced baseline TSS values over 4 weeks (Figure 2). 
Overall, the mean±SD TSS reduction was -3.2±3.7, with no significant differences among 
treatments. Mean TSS value observed 1 and 2 weeks after bilastine was significantly 
(P<0.05) lower than after montelukast. (Figure 2). Mean TSS values decreased similarly with 
all treatments after 3 weeks (Figure 2). However, bilastine reduced baseline TSS more than 
montelukast after 1 and 2 weeks of treatment (P always <0.05). Similar findings were 
observed for DNSS and DNNSS (data not shown).  Mean AQLQ increased similarly with all 
treatments after 4 and 12 weeks. The use of rescue medications for SARC and/or asthma did 
not differ among treatments, as was patients’ compliance with treatments (98.3 % overall). 
Drug-related incidence of adverse events was similar among the treatment groups (4.3% 
overall). No clinically significant changes in any laboratory tests, ECGs, or vital signs were 
note. 
 
We compared for the first time the efficacy and safety of concomitant administration of 
bilastine with montelukast versus respective monotherapies in a large population of patients 
with SARC and asthma. Contrary to our original hypothesis, concomitant administration of 
bilastine with montelukast was effective as either agent alone in the treatment of SARC 
symptoms. The reason(s) for not showing any additive effects of bilastine plus montelukast 
compared with each agent alone could be likely related to the overall mild intensity of SARC 
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symptoms at baseline that might have reduced the room for improvement thus limiting the 
probability to detect differences between treatments. The absolute extent of the effect of 
treatments on symptoms or on the use of rescue medications are impossible to gauge as a 
placebo arm was not included. Noteworthy, the improvement in TSS values observed in our 
study is similar to that obtained after 2 weeks of placebo treatment by Bachert et al. [9]. 
Although the underlying cause is unclear, the large placebo effect observed by Bachert et al. 
[9] is not uncommon as observed in other studies with SARC patients [11].  
 
 Bilastine alone improved SARC symptoms more than montelukast in the first 2 weeks of 
treatment. This finding is consisted with a more rapid effect of bilastine than montelukast, 
which may be of relevance for patients who need intermittently treatment to alleviate SARC 
symptoms. The absolute extent of the effect of these treatments on symptomatology or the 
use of rescue medication when treating SARC and concomitant asthma are impossible to 
gauge from this study because a group of patients treated entirely with placebo was not 
included. Moreover, since changes in lung function were not monitored, it is difficult to 
gauge how far this improvement reflected possible effects of study treatments on 
bronchoconstriction and/or lower airways inflammation or how far they reflected a true 
placebo effect. Previous reports suggest that an improvement in SARC can also improve 
asthma control [12]. Thus, due to its beneficial effects on SARC symptoms, our results 
suggest that bilastine, when added to inhaled corticosteroids alone or in combination with 
long-term β2-adrenergic bronchodilators, could improve disease control in mild-to-moderate 
asthma patients.  
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In conclusion, treatment with bilastine plus montelukast over 4 weeks does not 
consistently produce further improvements in SARC symptoms and AQLQ beyond those 
provided by either agents alone. Thus, there is no benefit of using bilastine plus montelukast 
to provide relief of SARC symptoms in partially controlled, mild-to-moderate asthma 
patients.  
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Figure legends 
Figure 1. Study design and treatment  
 
Figure 2.  Mean (SD) total symptom score (TSS, panel A) and asthma quality of life 
questionnaire (AQLQ, panel B) values in patients treated with bilastine plus montelukast and 
in those treated with bilastine or montelukast alone. Estimated (SEM) changes in TSS and 
AQLQ from the corresponding baseline values observed after each week of treatment with 
bilastine, montelukast or bilastine plus montelukast are depicted in panel C and D, 
respectively. B, baseline; *, P,0.05 comparing TSS values in bilastine vs montelukast after 1 
week of treatment; #, P<0.001 comparing TSS values observed 4 weeks after treatment with 
bilastine plus montelukast, bilastine or montelukast alone versus corresponding baseline 
values.  
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